Reports

Sale

Malignant Mesothelioma Therapeutics Market

Global Malignant Mesothelioma Therapeutics Market Analysis: By Application: Hospital Pharmacies, Retail Pharmacies, Oncology Centers, Others; By Product: Chemotherapy, Other Therapeutics; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis, Key Indicators for Demand; Competitive Landscape; 2024-2032

Global Malignant Mesothelioma Therapeutics Market Outlook

The global malignant mesothelioma therapeutics market is projected to grow at a CAGR of 7.5% in the forecast period of 2024-2032.

 

Global Malignant Mesothelioma Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The rising awareness regarding the treatment of mesothelioma and the availability of advanced therapeutics procedures is expected to aid the industry over the forecast period. Further, the use of asbestos in various products and sectors, which is a major cause for the development of mesothelioma, is expected to drive the global market for malignant mesothelioma therapeutic.

 

Market Segmentation

Malignant mesothelioma is a tumour that develops in the linings of the lungs, stomach, or heart due to exposure to or inhalation of asbestos. The treatment of mesothelioma can improve the patient’s quality of life and offers enhanced life expectancy. The global malignant mesothelioma therapeutics market can be divided based on segments like product and application.

 

Global Malignant Mesothelioma Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The industry is divided based on its product as chemotherapy and other therapeutics.

The industry can be broadly categorised based on its application into:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Oncology Centres
  • Other

The EMR report looks into the regional malignant mesothelioma therapeutics markets like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.

 

Market Analysis

The growing incidence of malignant mesothelioma among individuals, globally, is driving the industry for malignant mesothelioma therapeutics. One of the main trends in the market is the growing consciousness regarding malignant mesothelioma among individuals owing to efforts of various organisations conducting awareness programmes about cancer and cancer-causing agents such as asbestos, and their effective treatment. A number of screening programs are being conducted for people who are regularly exposed to asbestos, which finds application in building materials, machines, and transport vehicles in the form of hydrated silicates and long thin fibres, to prevent the disease from progressing to advanced stages. Further, the manufacturers and major players in the industry are focusing on the development of novel therapies with fewer side effects and elevated efficacy, which is expected to aid the industry over the forecast period further.

 

Global Malignant Mesothelioma Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global malignant mesothelioma therapeutics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Bristol-Myers Squibb Co. (NYSE: BMY)
  • Eli Lilly and Co. 
  • F. Hoffmann-La Roche Ltd. 
  • Merck & Co. Inc. 
  • Pfizer Inc. 
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Application
  • Product
  • Region
Breakup by Application
  • Hospital Pharmacies
  • Retail Pharmacies
  • Oncology Centers
  • Others
Breakup by Product
  • Chemotherapy
  • Other Therapeutics
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co. 
  • F. Hoffmann-La Roche Ltd. 
  • Merck & Co. Inc. 
  • Pfizer Inc. 
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Malignant Mesothelioma Therapeutics Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Malignant Mesothelioma Therapeutics Historical Market (2018-2023) 
    8.3    Global Malignant Mesothelioma Therapeutics Market Forecast (2024-2032)
    8.4    Global Malignant Mesothelioma Therapeutics Market by Application
        8.4.1    Hospital Pharmacies
            8.4.1.1    Historical Trend (2018-2023)
            8.4.1.2    Forecast Trend (2024-2032)
        8.4.2    Retail Pharmacies
            8.4.2.1    Historical Trend (2018-2023)
            8.4.2.2    Forecast Trend (2024-2032)
        8.4.3    Oncology Centers
            8.4.3.1    Historical Trend (2018-2023)
            8.4.3.2    Forecast Trend (2024-2032)
        8.4.4    Others
    8.5    Global Malignant Mesothelioma Therapeutics Market by Product
        8.5.1    Chemotherapy
            8.5.1.1    Historical Trend (2018-2023)
            8.5.1.2    Forecast Trend (2024-2032)
        8.5.2    Other Therapeutics    
    8.6    Global Malignant Mesothelioma Therapeutics Market by Region
        8.6.1    North America
            8.6.1.1    Historical Trend (2018-2023) 
            8.6.1.2    Forecast Trend (2024-2032)
        8.6.2    Europe
            8.6.2.1    Historical Trend (2018-2023) 
            8.6.2.2    Forecast Trend (2024-2032)
        8.6.3    Asia Pacific
            8.6.3.1    Historical Trend (2018-2023) 
            8.6.3.2    Forecast Trend (2024-2032)
        8.6.4    Latin America
            8.6.4.1    Historical Trend (2018-2023) 
            8.6.4.2    Forecast Trend (2024-2032)
        8.6.5    Middle East and Africa
            8.6.5.1    Historical Trend (2018-2023) 
            8.6.5.2    Forecast Trend (2024-2032) 
9    North America Malignant Mesothelioma Therapeutics Market Analysis
    9.1    United States of America 
        9.1.1    Historical Trend (2018-2023) 
        9.1.2    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Historical Trend (2018-2023) 
        9.2.2    Forecast Trend (2024-2032)
10    Europe Malignant Mesothelioma Therapeutics Market Analysis
    10.1    United Kingdom
        10.1.1    Historical Trend (2018-2023) 
        10.1.2    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Historical Trend (2018-2023) 
        10.2.2    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Historical Trend (2018-2023) 
        10.3.2    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Historical Trend (2018-2023) 
        10.4.2    Forecast Trend (2024-2032)
    10.5    Others
11    Asia Pacific Malignant Mesothelioma Therapeutics Market Analysis
    11.1    China
        11.1.1    Historical Trend (2018-2023) 
        11.1.2    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Historical Trend (2018-2023) 
        11.2.2    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Historical Trend (2018-2023) 
        11.3.2    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Historical Trend (2018-2023) 
        11.4.2    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.1    Historical Trend (2018-2023) 
        11.5.2    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Malignant Mesothelioma Therapeutics Market Analysis
    12.1    Brazil
        12.1.1    Historical Trend (2018-2023) 
        12.1.2    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Historical Trend (2018-2023) 
        12.2.2    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Historical Trend (2018-2023) 
        12.3.2    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East and Africa Malignant Mesothelioma Therapeutics Market Analysis
    13.1    Saudi Arabia
        13.1.1    Historical Trend (2018-2023) 
        13.1.2    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Historical Trend (2018-2023) 
        13.2.2    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Historical Trend (2018-2023) 
        13.3.2    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Historical Trend (2018-2023) 
        13.4.2    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Value Chain Analysis
16    Competitive Landscape

    16.1    Market Structure
    16.2    Company Profiles
        16.2.1    Bristol-Myers Squibb Company
            16.2.1.1    Company Overview
            16.2.1.2    Product Portfolio
            16.2.1.3    Demographic Reach and Achievements
            16.2.1.4    Certifications
        16.2.2    Eli Lilly and Company
            16.2.2.1    Company Overview
            16.2.2.2    Product Portfolio
            16.2.2.3    Demographic Reach and Achievements
            16.2.2.4    Certifications
        16.2.3    F. Hoffmann-La Roche Ltd
            16.2.3.1    Company Overview
            16.2.3.2    Product Portfolio
            16.2.3.3    Demographic Reach and Achievements
            16.2.3.4    Certifications
        16.2.4    Merck and Co., Inc.
            16.2.4.1    Company Overview
            16.2.4.2    Product Portfolio
            16.2.4.3    Demographic Reach and Achievements
            16.2.4.4    Certifications
        16.2.5    Pfizer Inc.
            16.2.5.1    Company Overview
            16.2.5.2    Product Portfolio
            16.2.5.3    Demographic Reach and Achievements
            16.2.5.4    Certifications
        16.2.6    Others
17    Key Trends and Developments in the Market

 

List of Key Figures and Tables

1.    Global Malignant Mesothelioma Therapeutics Market: Key Industry Highlights, 2018 and 2032
2.    Global Malignant Mesothelioma Therapeutics Historical Market: Breakup by Application (USD Billion), 2018-2023
3.    Global Malignant Mesothelioma Therapeutics Market Forecast: Breakup by Application (USD Billion), 2024-2032
4.    Global Malignant Mesothelioma Therapeutics Historical Market: Breakup by Product (USD Billion), 2018-2023
5.    Global Malignant Mesothelioma Therapeutics Market Forecast: Breakup by Product (USD Billion), 2024-2032
6.    Global Malignant Mesothelioma Therapeutics Historical Market: Breakup by Region (USD Billion), 2018-2023
7.    Global Malignant Mesothelioma Therapeutics Market Forecast: Breakup by Region (USD Billion), 2024-2032
8.    North America Malignant Mesothelioma Therapeutics Historical Market: Breakup by Country (USD Billion), 2018-2023
9.    North America Malignant Mesothelioma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2024-2032
10.    Europe Malignant Mesothelioma Therapeutics Historical Market: Breakup by Country (USD Billion), 2018-2023
11.    Europe Malignant Mesothelioma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2024-2032
12.    Asia Pacific Malignant Mesothelioma Therapeutics Historical Market: Breakup by Country (USD Billion), 2018-2023
13.    Asia Pacific Malignant Mesothelioma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2024-2032
14.    Latin America Malignant Mesothelioma Therapeutics Historical Market: Breakup by Country (USD Billion), 2018-2023
15.    Latin America Malignant Mesothelioma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2024-2032
16.    Middle East and Africa Malignant Mesothelioma Therapeutics Historical Market: Breakup by Country (USD Billion), 2018-2023
17.    Middle East and Africa Malignant Mesothelioma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2024-2032
18.    Global Malignant Mesothelioma Therapeutics Market Structure

Key Questions Answered in the Report

The global malignant mesothelioma therapeutics market is projected to grow at a CAGR of 7.5% between 2024 and 2032.

The major drivers include the increasing cases of malignant mesothelioma, the increasing awareness regarding cancer treatment, the growing utilisation of asbestos in various sectors, and growing technological advancements.

The growing investments in the development of novel therapies to treat mesothelioma are key trends guiding the growth of the market.

The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Chemotherapy and other therapeutics are the significant products of malignant mesothelioma therapeutics.

The major applications of the product include hospital pharmacies, retail pharmacies, and oncology centres, among others.

The key market players include Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck and Co., Inc., and Pfizer Inc., among others.

Analyst Review

The global malignant mesothelioma therapeutics market is being driven by the rising prevalence of malignant mesothelioma, and the growing awareness regarding its treatment owing to various initiatives taken by the government aided organisations. Aided by the growing research and development of novel therapies, the market is expected to witness a robust growth in the forecast period of 2024-2032, growing at a CAGR of 7.5%.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on product, the industry can be bifurcated into chemotherapy and other therapeutics. On the basis of application, the industry is divided into hospital pharmacies, retail pharmacies, and oncology centres, among others. The major regional markets for malignant mesothelioma therapeutics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., and others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER